$14.25
$14.24
$14.58
$9.11
$6.0B
25.18%
This is a preview of the full version of Prosperse
Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to the proposed sales of R1 RCM Inc. and Enstar Group Limited.
N/A
Aug 12, 2024
Brodsky & Smith is investigating several companies regarding potential breaches of fiduciary duties by their boards in acquisition deals, including Revance Therapeutics, Greenbrook TMS, R1 RCM, and Enstar Group.
N/A
Aug 12, 2024
Brodsky & Smith is investigating the proposed acquisitions of R1 RCM Inc., Enstar Group Limited, Premier Financial Corp., and The First Bancshares, Inc. to determine if the respective boards breached their fiduciary duties by failing to conduct a fair process and ensure shareholders are receiving fa...
N/A
Aug 5, 2024
The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of R1 RCM to TowerBrook Capital Partners and Clayton, Dubilier & Rice for $14.30 per share, which is below the price targets set by Wall Street analysts.
Wohl & Fruchter Llp
Aug 1, 2024
The article provides an analysis of 8 analysts' insights on R1 RCM, a provider of technology-driven solutions for healthcare providers. The analysts have a mix of bullish and bearish perspectives, with an average 12-month price target of $17.38 and a range of $15.00 to $20.00.
Benzinga Insights, Benzinga Staff Writer
Jul 22, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024
Date: Oct 24, 2024